Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.

@article{Liu2013MolecularMA,
  title={Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation.},
  author={Qifa Liu and Li Xuan and Hui Liu and Fen Huang and Hongsheng Zhou and Zhi-ping Fan and Ke Zhao and Meiqing Wu and Lanping Xu and Xiao Zhai and Fuhua Zhang and Can Liu and Jing Sun and Xiaojun Huang},
  journal={American journal of hematology},
  year={2013},
  volume={88 7},
  pages={550-5}
}
The optimal preemptive therapy for Epstein-Barr virus (EBV)-associated diseases remains under discussion. We developed a stepwise preemptive therapy (antiviral agents and reduction of immunosuppressants [RI] followed by rituximab) for EBV viremia, based on duration of EBV viremia and changes of viral loads. The blood EBV-DNA loads were regularly monitored by quantitative real-time polymerase chain reaction in 251 recipients undergoing allogeneic stem cell transplantation. The 3-year cumulative… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Similar Papers

Loading similar papers…